J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text HTML] [Full Text PDF] （in Japanese / 753KB） [PDF: Members Only]

J.Jpn. Surg. Soc.. 124(3): 261-267, 2023

Feature topic

STRATIFIED MEDICINE FOR PATIENTS WITH HEPATOBILIARY AND PANCREATIC CANCER: PRESENT AND FUTURE

Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan

Daisaku Yamada, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Yoshito Tomimaru, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi

Hepatobiliary pancreatic cancers (HBPCs) are lethal malignancies that are difficult to detect early and with frequent recurrence after surgery. The development of nonsurgical treatment of these cancers is an urgent issue, and precision medicine for patients divided into treatment susceptibility classes would be an optimal treatment strategy, called stratified medicine. Although stratified medicine for HBPC patients has not yet been developed, targeted therapies against genetic mutations of HBPCs are now making steady progress. In this article, we introduce recent findings and clinical studies concerning genomic therapies for patients with HBPCs and expect treatments for HBPCs in the near future.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.